ProQR Therapeutics (PRQR) Osake Kurssi
ProQR Therapeutics Kurssi
Liikevaihto on kasvanut 61,5 % vuodessa viimeisten 13 vuoden aikana 15,28 M EUR:een. ProQR Therapeuticsn nettomarginaali on nyt −265,2 %, noussut −4 549,8 %:sta muutama vuosi sitten. Analyytikoiden mediaanitavoitehinta on 2,67 EUR, eli yli nykyhintaa 118,3 %. 16 analyytikosta 15 suosittaa ostoa — kokonaiskonsensus on Osta.
ProQR Therapeutics osakekurssi
Hae nämä tiedot Eulerpool API:n kautta
100 000 pyyntöä/kk ilmaiseksi · ei luottokorttia
ProQR Therapeutics liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset ProQR Therapeutics -osakkeesta
The business model of ProQR Therapeutics NV is centered around developing RNA-based therapeutics to treat rare and genetic diseases. By utilizing proprietary RNA repair technologies, the company aims to target specific genetic defects and correct them at the molecular level. ProQR Therapeutics NV conducts extensive research and clinical trials to develop innovative treatments for various conditions, including cystic fibrosis, Leber's congenital amaurosis, and rare forms of genetic blindness. Through strategic partnerships, they aim to advance their pipeline of candidate therapies and ultimately improve the lives of patients affected by these diseases.
ProQR Therapeutics NV is primarily active in the biotechnology industry.
The main competitors of ProQR Therapeutics NV in the market are Editas Medicine, Ionis Pharmaceuticals, and Vertex Pharmaceuticals.
ProQR Therapeutics NV is a leading biotech company focused on developing innovative RNA-based therapies to treat genetic diseases. Founded in 2012 and headquartered in the Netherlands, ProQR pioneers the development of RNA therapies by leveraging a proprietary technology platform. The company's objective is to address the root cause of diseases at the genetic level, aiming to transform the lives of patients with severe genetic disorders. ProQR's pipeline comprises targeted therapies for a variety of indications, including rare eye diseases, cystic fibrosis, and genetic muscle disorders. With its commitment to advancing groundbreaking treatments, ProQR Therapeutics NV stands at the forefront of biotech innovation.
ProQR Therapeutics NV, a leading biopharmaceutical company, has achieved several significant milestones. Notably, the company successfully completed a Phase 1b clinical trial for its Usher syndrome therapy, QR-421a. It also advanced its RNA therapeutics for cystic fibrosis (QR-010) into Phase 2 trials, showcasing promising results. ProQR Therapeutics NV received Fast Track designation from the U.S. FDA for its Leber Congenital Amaurosis program (QR-110), accelerating its development. Moreover, the company's QR-313 therapeutic, targeting dystrophic epidermolysis bullosa, obtained Orphan Drug designation from the FDA and European Medicines Agency. ProQR Therapeutics NV's commitment to innovative solutions and achieving significant clinical milestones positions it favorably in the pharmaceutical industry.
ProQR Therapeutics NV is primarily present in multiple countries and regions globally. The company has a strong presence in Europe, with headquarters in the Netherlands. It operates extensively within the European Union, including countries like Germany, France, and the United Kingdom. ProQR has also expanded its reach into North America, specifically the United States. Additionally, the company has established a presence in various international markets, such as Japan. ProQR Therapeutics NV's global presence allows it to access diverse markets and collaborate with partners worldwide to advance its innovative therapies and treatments.
ProQR Therapeutics NV is committed to transforming the lives of patients with severe genetic diseases. Their corporate philosophy revolves around innovation, collaboration, and dedication to scientific excellence. With a focus on RNA therapies, ProQR Therapeutics NV aims to develop life-changing treatments using proprietary technologies and expertise. Their values include patient-centricity, integrity, and a strong sense of responsibility towards their stakeholders. By leveraging their extensive knowledge and strategic partnerships, ProQR Therapeutics NV strives to address unmet medical needs and improve the quality of life for individuals affected by genetic disorders.
Analyytikot asettavat tällä hetkellä ProQR Therapeutics-osakkeelle keskimääräisen tavoitehinnan 2,67 EUR (mediaani: 2,67 EUR), mikä merkitsee +118,3 % viimeisimpään hintaan verrattuna. Konsensus perustuu 16 analyytikkoarvioon.
16 analyytikkoa arvioi tällä hetkellä ProQR Therapeutics-osaketta: 15 suosittaa ostoa, 1 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat ProQR Therapeutics-yhtiöltä 16,75 M EUR liikevaihtoa ja −0,43 EUR osakekohtaista tulosta.
ProQR Therapeutics-osake (PRQR) on listattuna 4 pörssissä, muun muassa: NASDAQ (PRQR), Frankfurt (0PQ.F), München (0PQ.MU), Düsseldorf (0PQ.DU).
ProQR Therapeutics NV is a biopharmaceutical company that focuses on RNA-based therapeutics for the treatment of genetically inherited diseases. With over a decade of company history, it has become one of the leading companies in the field of RNA medicine. The business model of ProQR Therapeutics NV is based on the discovery, development, and commercialization of RNA technologies and products. With a strong focus on identifying genetic mutations that lead to diseases, the company focuses on developing RNA-based therapies to treat these diseases. One area that the company focuses on is ophthalmological research. ProQR Therapeutics NV has established itself as a pioneer in RNA medicine for the treatment of eye diseases. The company has developed an RNA technology platform called "Axiomer" specifically to enable the treatment of retinal diseases. Another area that ProQR Therapeutics NV focuses on is pulmonary research. The company hopes to provide life-changing treatments for patients with cystic fibrosis and other pulmonary diseases through RNA therapies. The company also has a strong presence in nephrology. An RNA therapeutic has been developed to treat IQ motif-containing GTPase-activating protein 2 (IQGAP2), which is a key factor in the development of a rare and severe progressive kidney disease called ADPKD (autosomal dominant polycystic kidney disease). In addition, the company works closely with leading research and development institutions to further develop and improve RNA technologies. ProQR Therapeutics NV has partnerships with various renowned institutions, including the National Institutes of Health (NIH), the Cystic Fibrosis Foundation, and the Usher Syndrome Coalition Program. The company has already developed several RNA therapeutics and is bringing these products to market. One such product is QR-010, for which ProQR Therapeutics NV has received an Orphan Drug Designation. The medication is intended for patients with cystic fibrosis and is currently in clinical phase 2b/3. Another product, QR-313, is also in clinical phase for patients with epidermolytic ichthyosis. In addition to these RNA therapeutics, the company also has a robust pipeline for further RNA-based therapies in various stages of development. The company plans to bring these products to market in the coming years. Overall, ProQR Therapeutics NV has a solid business model based on innovative RNA technologies and the development of life-changing therapies for patients with rare and severe diseases. With a strong presence in ophthalmology, nephrology, and pulmonology, and a wide range of RNA products in development, the company seems well-positioned to continue its growth in the coming years.
odotettu liikevaihto ProQR Therapeutics on 16,75 M EUR. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
odotettu voitto ProQR Therapeutics on −44,36 M EUR. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
ProQR Therapeutics:n hinta-voitto-suhde (P/E) on tällä hetkellä −2,84. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan ProQR Therapeutics-osakkeen arvostusta.
ProQR Therapeutics:n hinta-myynti-suhde (P/S) on tällä hetkellä 7,53. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii ProQR Therapeutics-osakkeen arvostuskennuslukuna.
ProQR Therapeutics:n Eulpool-laatuscore on 3/10.
ProQR Therapeutics:n ISIN on NL0010872495. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
ProQR Therapeutics:n WKN on A12B97. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
ProQR Therapeutics:n ticker on PRQR. Tämä pörssinoteeraus käytetään ProQR Therapeutics-osakkeiden kauppaan pörssissä.
ProQR Therapeutics osake
ProQR Therapeutics vertaisryhmä
ProQR Therapeutics Ticker
ProQR Therapeutics FIGI
Kaikki tunnusluvut ja syvällinen analyysi ProQR Therapeutics:sta
Meidän osakeanalyysimme ProQR Therapeutics-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut ProQR Therapeutics:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: